Home    Back

Candesartan plus non-ccb agents    (DrugBank: Candesartan)

2 diseases
IDDisease name (Link within this page)Number of trials
58Hypertrophic cardiomyopathy0
67Polycystic kidney disease1

58. Hypertrophic cardiomyopathy    [ 92 clinical trials,   126 drugs,   (DrugBank: 35 drugs),   40 drug target genes,   141 drug target pathways]
Searched query = "Hypertrophic cardiomyopathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 92 trial found

67. Polycystic kidney disease    [ 186 clinical trials,   196 drugs,   (DrugBank: 47 drugs),   35 drug target genes,   146 drug target pathways]
Searched query = "Polycystic kidney disease", "PKD", "PCKD", "Polycystic kidney", "ADPKD", "ARPKD"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 186 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00541853
(ClinicalTrials.gov)		December 20079/10/2007CCB Safety Study in Treatment of Hypertension of ADPKDComparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD PatientsKidney, Polycystic, Autosomal DominantDrug: Candesartan;Drug: Candesartan and Cilnidipine;Drug: Candesartan plus non-CCB agentsKyorin UniversityMinistry of Health, Labour and Welfare, JapanNot yet recruiting20 Years60 YearsBoth150Phase 4Japan